🏛️ Verified NIH Record • Updated 2024-11-14
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial (NCT06026254)
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: ImmuneSensor Therapeutics Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (3 items).
Location: Honor Health — Scottsdale, Arizona
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Permanently discontinued from IMSA101 treatment in parent protocol IMSA101-101 for any reason other than enrollment in the rollover study
- Failure to meet the criteria specified in parent protocol IMSA101-101 for continued study treatment
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (2 Sites)
- Honor Health — Scottsdale, Arizona
- UC San Diego Moores Cancer Center — La Jolla, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.